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Abstract
BACKGROUND—Use of risk assessment tools, such as the Caprini score or Rogers score, is 
recommended by national societies to stratify surgical patients by venous thromboembolism 
(VTE) risk and guide prophylaxis. However, these tools were not developed in a gynecologic 
oncology patient population and their utility in this population is unknown.
OBJECTIVE—To examine the ability of both the Caprini and Rogers score to stratify 
gynecologic oncology patients by risk of VTE.
STUDY DESIGN—Patients undergoing surgery for cervical, ovarian, uterine, vaginal and vulvar 
cancers between 2008 and 2013 were identified from the National Surgical Quality Improvement 
Database using ICD-9 codes. Caprini and Rogers scores were calculated for each patient based 
upon recorded demographic and procedure data. VTE events were recorded for 30 days 
postoperatively. Patients were categorized into risk groups based on calculated Caprini and Rogers 
scores and the incidence of VTE and 95% confidence interval was estimated for each of these 
groups. The relationship between risk score and VTE incidence was examined with Pearson’s 
correlation coefficient.
RESULTS—Of 17,713 patients, 1.8% developed a VTE. No patients were classified by the 
Caprini score as low risk, 0.1% were moderate risk, 3.0% were higher risk (score 4), and 96.9% 
were highest risk (score >=5). The Caprini score groupings did not correlate with VTE. The high-
risk group had a paradoxically higher incidence of VTE of 2.5% compared to the highest risk 
group, 1.7% (p=0.40). However, when the highest risk group of the Caprini score was sub-
stratified, it was highly correlated with VTE (R2=0.93). For the Rogers score, only 0.2% of 
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patients were low risk (score <7), 36.9% were medium risk (score 7–10), and 63.0% were high-
risk (score >10). When the highest risk group of the Rogers score was sub-stratified, it was also 
highly correlated with VTE (R2=0.99).
CONCLUSIONS—Gynecologic oncology patients score very high on current VTE risk 
assessment models. The Caprini score is limited in its ability to discriminate relative VTE risk 
among gynecologic oncology patients as 97% are in the highest-risk category. Sub-stratification of 
the highest risk groups allows for relative VTE risk stratification among gynecologic oncology 
patients suggesting that further evaluation of risk stratification is needed in gynecologic oncology 
surgery.
Keywords
venous thromboembolism; risk assessment model; Caprini score; Rogers score; gynecologic 
oncology surgery
INTRODUCTION
Venous thromboembolism (VTE) is the second most common complication and third most 
common cause of excess mortality after surgery (1). Patients with gynecologic cancer are at 
an increased risk of thromboembolism. National organizations, such as the American 
College of Chest Physicians (ACCP), have published guidelines for the appropriate use of 
postoperative mechanical and pharmacologic prophylaxis (2). Within these guidelines, risk 
stratification is used to determine the appropriate degree of prophylaxis for each individual 
patient. Those patients at the highest risk (~6% risk of VTE) are recommended to receive 
dual prophylaxis with both mechanical and pharmacologic prophylaxis including extended 
duration pharmacologic prophylaxis for those with pelvic cancers. Populations at low risk 
(~1.5% risk of VTE) are recommended to receive only mechanical prophylaxis.
The risk stratification tools used in the ACCP guidelines are the Caprini score and the 
Rogers score (3–5). Both the Caprini and the Rogers models assign points to various risk 
factors for VTE and use those point totals to place patients into risk strata. The Caprini score 
is the most widely used VTE risk assessment tool (6–8). The Rogers score was developed 
from vascular and general surgery cases recorded in a large Veterans Administration quality 
database and is used less frequently (3). The authors of ACCP guidelines note that although 
risk stratification models have not been validated in gynecologic surgery patients, 
gynecologic surgery patients are likely sufficiently similar to other patients undergoing 
abdominal and pelvic surgery for extrapolation (2). However, neither score was developed in 
a gynecologic oncology patient population and the validity of this extrapolation hypothesis 
is unknown.
Two studies have examined the use of the Caprini score in gynecologic oncology patients. 
Both found that gynecologic oncology patients score high using the Caprini risk assessment 
model with >92% and >96% falling into the highest risk category, suggesting a limited 
ability to risk stratify as the vast majority of patients are categorized in a single stratum (9, 
10). However, further examination into the possibility of risk stratification within this 
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highest risk category has not been performed and the Rogers score has yet to be examined in 
a gynecologic oncology patient population.
Our objective was to examine the utility of the Caprini and Rogers scores to risk stratify 
gynecologic oncology patients undergoing surgery by their risk of postoperative VTE.
MATERIALS AND METHODS
This was a secondary analysis cohort study of prospectively collected surgical quality data. 
The primary outcome was the association between risk assessment score in two different risk 
assessment models and the incidence of VTE. The study population was patients who 
underwent surgery for cervical, ovarian, uterine, vaginal and vulvar cancers between 2008 
and 2013 who were identified from the American College of Surgeons National Surgical 
Quality Improvement Program (ACS-NSQIP) Database using International Classification of 
Diseases, Ninth Revision (ICD-9) codes. The Institutional Review Board at the University of 
North Carolina at Chapel Hill reviewed this study and declared it exempt from formal review 
as it does not constitute human subjects research.
The ACS-NSQIP database is a national surgical quality improvement project. Participation 
is voluntary and participating institutions are able to track their own risk-adjusted outcomes 
after surgery. Trained clinical reviewers prospectively collect variables such as patient 
demographics, operative variables and post-operative outcomes for each individual 
procedure for 30 days following surgery. The data is then de-identified of patient, hospital, 
and location-specific information and placed into the NSQIP database. Periodic auditing 
ensures high quality data, including that for data points occurring after hospital discharge. 
Details of methods of data collection and reliability have been previously reported (11).
Our primary outcome was VTE which was defined as either a pulmonary embolism or a 
deep vein thrombosis diagnosed within 30-days postoperatively. Both were defined as per 
the NSQIP participant use file (12). Demographic, operative and disease characteristics were 
also recorded. Site of malignancy was defined by postoperative ICD-9 code. Procedure type 
was defined as laparotomy, minimally invasive and external. Patients were placed into these 
categories based on primary procedure Current Procedural Terminology (CPT) codes. 
Minimally invasive procedures were defined as laparoscopic or vaginal approaches with 
abdominal cavity entry, such as a vaginal hysterectomy or operative laparoscopy. External 
procedures were defined as procedures in which the abdominal cavity was not entered, such 
as vulvar/vaginal resections, or cervical excisional procedures. Charlson comorbidity score 
was calculated for each patient as previously described (13, 14). Surgical complexity was 
defined by the work relative value unit (wRVU) which is an estimate of the amount of 
physician work per CPT code. The wRVU for each procedure is the sum of the assigned 
value to each CPT code for the procedure, thus higher wRVU is associated with increasing 
surgical complexity.
A Caprini score and a Rogers score was calculated for each patient by assigning points to 
each risk factor present for a given patient. The Caprini score model was used to calculate a 
Caprini risk score for each patient based on the variables available in the NSQIP database 
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(Supplementary Table 1). Risk factors that are assigned points in the Caprini score, but are 
unavailable in NSQIP, include swollen legs, varicose veins, history of unexplained abortions 
(>3), use of hormonal contraceptives or replacement, history of inflammatory bowel disease, 
central venous access, history of VTE or family history VTE, and congenital or acquired 
thrombophilias. Data was missing for less than 5% of patients for all available risk factors in 
the Caprini model. The Rogers score model was used to calculate a Rogers risk score for 
each patient based on the variables available in the NSQIP database (Supplementary Table 
2). All risk factors included in the Rogers score are available in NSQIP. For the Rogers 
model, data was missing for less than 5% for all risk factors with the exception of serum 
albumin and bilirubin which were missing for ~40% of patients. Patients missing these 
laboratory values were given zero points for that risk factor. As there are 18 measured risk 
factors in the Rogers score worth 1–4 points and both hyperbilirubinemia and 
hypoalbuminemia are worth only 1 point and are relatively rare in the population (17% and 
5% respectively), having the additional data for these two variables should not alter the total 
Rogers score sufficiently to change our conclusions.
Data regarding mechanical or pharmacologic prophylaxis is not available in the NSQIP 
database. However, Surgical Care Improvement Project (SCIP) guidelines that were 
implemented in 2008 require the use of VTE prophylaxis or documentation of why 
prophylaxis was not provided (15). We assume that the compliance with these guidelines 
was very high (>95%) due to the penalties imposed on hospitals and thus, the majority of the 
patients in this cohort likely received VTE prophylaxis (16).
After risk scores were calculated for each patient, patients were categorized into the 
American College of Chest Physicians risk stratification groups based upon their Caprini or 
Rogers score individually. Patients were also categorized into risk categories by their 
individual scores. The incidence of VTE for each of these risk groups was estimated along 
with a 95% confidence interval. The relationship between risk score and VTE incidence was 
examined using Pearson’s correlation coefficient. For bivariable analysis, 2-tailed t-tests 
were used for continuous variables and Pearson’s chi square tests for categorical variables. 
A p value of less than 0.05 was considered significant for all analyses. SPSS version 20.0 
(IBM Corp, Armonk, NY) was used for all analyses.
RESULTS
We identified 17,713 patients with the demographic and operative characteristics as listed in 
Table 1. The majority of the patients in this cohort had uterine cancer (59.5%) followed by 
ovarian cancer (27.2%), cervical cancer (8.8%) and vulvar/vaginal (4.5%) cancer. Surgical 
approach was laparotomy (52.3%), minimally invasive (43.0%) and external procedures 
(4.7%). This cohort also represents a group of patients undergoing surgically complex 
procedures. The median work relative value unit was 31.5 (interquartile range 19.3–38.0). 
For reference, the number of work relative value units assigned to a total abdominal 
hysterectomy is 17.3. Therefore, the majority of these procedures were complicated 
oncologic procedures.
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Of 17,713 patients with gynecologic cancer, 1.8% (n=313) developed VTE. One hundred 
and thirty one patients experienced a PE, 149 experienced a DVT and 33 experienced both a 
PE and a DVT. There were 143 deaths recorded in the 30-day postoperative period and VTE 
was associated with an increased risk of death. Patients with VTE experienced a 4.7% 30-
day mortality compared to 0.7% for patients without VTE (p<0.001). On bivariable analysis, 
cancer site was associated with VTE. Patients with ovarian cancer had the highest VTE 
incidence (3.0%) followed by vulvar/vaginal cancer patients (1.5%), uterine cancer patients 
(1.3%) and cervical cancer patients (1.2%)(p<0.001).
Surgical approach was also associated with VTE. Laparotomy patients had the highest VTE 
incidence (2.7%), followed by patients undergoing external procedures (1.1%) and those 
undergoing minimally invasive procedures (0.7%) (p<0.001). However, surgical approach is 
not factored into the Caprini score; thus, patients undergoing minimally invasive surgery had 
almost identical mean Caprini scores as patients undergoing laparotomy (6.5 versus 6.4, 
p=0.06). Rogers scores were significantly lower for patients undergoing minimally invasive 
surgery as compared to laparotomy, although the magnitude of the difference was small 
(10.6 versus 11.6, p<0.001).
Patients were classified into ACCP Guideline risk groups based first on their Caprini risk 
score and then by their Rogers risk score (Table 2). These guidelines classify patients 
undergoing non-orthopedic surgical procedures into 4 groups based on the risk of VTE and 
corresponding Caprini and Rogers scores for each group are given. The category patients 
were placed in was different depending on whether the Caprini score or the Rogers score 
was used. For the Caprini score, no patients were classified low risk, 0.1% were moderate 
risk, 3.0% were higher risk and the remaining 96.9% were highest risk. For the Rogers 
score, only 0.2% of patients were low risk, 36.9% were medium risk, and 63.0% were high 
risk (score >10).
Patients were then classified into the conventional risk groups described by the Caprini and 
Rogers score (Table 3). For the Caprini score, the higher risk group had a paradoxically 
higher incidence of VTE of 2.5% compared to the VTE incidence of the highest risk group, 
1.7% (p=0.40). For the Rogers score, VTE incidence increased with each increase in risk 
category and patients in the high risk group had a higher incidence of VTE (2.2%) than 
those in the moderate risk group (1.0%) (p<0.001).
Given the large number of patients in the highest risk groups for each score, these groups 
were substratified by score. VTE incidence rates were calculated for each score (Table 4). 
Among the patients in the highest risk groups VTE incidence was highly correlated with 
increasing risk score. For the Caprini score, this relationship was linear (R2=0.93) (Figure 
1). Those with a score of 8 or greater had an increased odds of experiencing a VTE 
compared to those with a score of 5 (OR 2.1). For the Rogers score, the relationship between 
score and VTE incidence was also linear and highly correlated (R2=0.99) (Figure 2). The 
odds of experiencing a VTE also increased for each increasing risk score. Those with a score 
of 15 or greater have 5.3 times the odds of experiencing a VTE as those with a score of 11.
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COMMENT
Gynecologic oncology patients score very high on currently available VTE risk assessment 
models. Using the conventional Caprini risk score groupings, 96.9% of gynecologic 
oncology patients are classified in the highest risk group with a score of ≥5. This finding is 
supported by two previous studies which found that >92% and >96% of patients operated on 
by a gynecologic oncologist were categorized in the highest Caprini risk groups (9, 10). For 
the Rogers score, 63.0% of patients are classified in the high-risk group with a score of ≥11. 
Given that the majority of gynecologic oncology patients score in the highest risk group, in 
the current groupings we cannot distinguish between gynecologic oncology patients at 
higher relative VTE risk and those at lower relative risk.
Risk stratification is a central principle of VTE prophylaxis in the current ACCP Guidelines 
(2). When we placed our gynecologic oncology patients into the ACCP risk categories, 
patients were categorized differently depending on whether the Caprini score or the Rogers 
score was used. Using the Caprini score, only 0.1% of the patients were very low or low 
risk, whereas for the Rogers score, 37.1% were classified as very low or low risk. This 
discrepancy makes it difficult for clinicians to use these ACCP recommended groupings in 
gynecologic oncology patients. Our data suggests the ACCP statement that the gynecologic 
surgery population is similar enough to those undergoing other abdominal or pelvic surgery 
to use the same risk groups is not valid among gynecologic oncology surgical patients. Thus, 
in the current ACCP paradigm, risk stratification, a fundamental principle of VTE 
prophylaxis, is not possible for gynecologic oncology patients.
However, when we examined the highest risk group for each of the risk assessment models 
by score we found that an increasing score is highly associated with VTE incidence. This 
suggests that these risk assessment models, while incorporating important risk factors for 
VTE, may not be assigning some risk factors appropriate weight. If these risk assessment 
models are altered by creating stratified scores within the highest risk groups, they may be 
more effective in discriminating the relative risk of VTE between different gynecologic 
oncology patients.
One possible variable that may unduely influence the risk calculation is the score assigned to 
minimally invasive surgery. Currently available risk assessment models also do not 
distinguish between minimally invasive surgery and laparotomy in terms of VTE risk, 
although studies have shown that the VTE risk is lower with minimally invasive surgery 
(17–19). In this study, although the observed incidence of VTE was markedly different 
between minimally invasive surgery patients and laparotomy patients, their mean Caprini 
and Rogers scores were not. The lack of differentiation between minimally invasive surgery 
and laparotomy is a target for improvement in future VTE risk assessment models for 
gynecologic oncology patients.
Risk stratification is needed for gynecologic oncology patients as modern VTE prophylaxis 
is not one size fits all, and prophylaxis has both risks and costs. Perioperative VTE 
prophylaxis for high-risk cancer patients can include the four following components: 
mechanical prophylaxis, preoperative pharmacologic prophylaxis, postoperative 
BARBER and CLARKE-PEARSON Page 6
Am J Obstet Gynecol. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
pharmacologic prophylaxis and extended duration pharmacologic prophylaxis for 28 days. 
The use of preoperative pharmacologic prophylaxis is associated with both a decrease in 
VTE incidence and in some studies, an increase in bleeding (20, 21). Although studies 
specific to gynecologic oncology and a recent large quality improvement project that 
included gynecologic oncology patients have not found a statistically significant increase in 
perioperative bleeding (22, 23). Extended duration prophylaxis has been shown to decrease 
the incidence of VTE among patients with cancer undergoing laparotomy, but is associated 
with significant costs and inconvenience and the trial supporting its use only contained a 
small percentage of gynecologic oncology patients (24, 25). Additionally, gynecologic 
oncology surgery is increasingly being performed with a minimally invasive approach (26, 
27). There are few who would argue that a healthy 45 year old with an early stage 
endometrial cancer undergoing laparoscopic hysterectomy would require all four of the 
prophylaxis components. In fact, some have argued that patients undergoing minimally 
invasive surgery for cancer do not require any prophylaxis as data to demonstrate benefit is 
not available for this population (28, 29). Strategies such as risk stratification within the 
highest risk group of both the Caprini or Rogers score or development of gynecologic 
oncology specific risk scores could allow us to tailor our VTE prophylaxis regimen to the 
VTE risk of our individual patients. Those at highest risk could be given all four components 
of perioperative prophylaxis whereas those at the lower risk could receive only mechanical 
prophylaxis. Improved risk stratification allows for appropriate utilization of the various 
methods of prophylaxis available while minimizing risks and costs.
Strengths of this study include a large cohort of gynecologic oncology patients in which to 
measure VTE incidence. Additionally, our data source is a large national quality database 
focused on measuring postoperative complications up to 30 days after surgery and thus has 
robust data regarding VTE events. This data source has been used to study VTE in the many 
surgical disciplines and was the data source used for the highly cited validation of the 
Caprini score in general surgery patients (7, 17, 19, 30, 31). Limitations of the study include 
the lack of data regarding VTE prophylaxis within NSQIP. Although, it is likely that as 
cancer patients undergoing surgery, nearly all patients received some form of prophylaxis as 
per the Surgical Care Improvement Guidelines. The use of prophylaxis is likely responsible 
for the relatively low incidence of VTE we observed. Additionally, NSQIP does not contain 
information regarding some of the Caprini model inputs and thus our calculated Caprini 
scores may underestimate the true Caprini score for a given patient. However, given that 
96.9% of patients were in the highest risk group, adding the data for these additional risk 
factors would only increase the percentage of patients in the highest risk group and enhance 
our hypothesis that risk stratification is limited if all patients are in the highest risk stratum.
Currently available risk assessment models with conventional risk groups have limited utility 
in a gynecologic oncology patient population as the majority of patients are in the highest 
risk groups. However, sub-stratification within the highest risk groups may provide valuable 
information about the relative risk of VTE between different groups of gynecologic 
oncology patients. Risk assessment model development specific to the gynecologic oncology 
patient that incorporates route of surgery will likely improve risk stratification.
BARBER and CLARKE-PEARSON Page 7
Am J Obstet Gynecol. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
FINANCIAL SUPPORT: Dr Barber is supported by NIH 5T32 HD040672-15.
References
1. Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries 
during hospitalization. Jama. 2003; 290(14):1868–74. [PubMed: 14532315] 
2. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, et al. Prevention of VTE in 
nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: 
American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 
141(2 Suppl):e227S–77S. [PubMed: 22315263] 
3. Rogers SO Jr, Kilaru RK, Hosokawa P, Henderson WG, Zinner MJ, Khuri SF. Multivariable 
predictors of postoperative venous thromboembolic events after general and vascular surgery: 
results from the patient safety in surgery study. Journal of the American College of Surgeons. 2007; 
204(6):1211–21. [PubMed: 17544079] 
4. Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Disease-a-month: DM. 
2005; 51(2–3):70–8. [PubMed: 15900257] 
5. Caprini JA, Arcelus JI, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for 
venous thromboembolic disease. Seminars in hematology. 2001; 38(2 Suppl 5):12–9. [PubMed: 
11449339] 
6. Obi AT, Pannucci CJ, Nackashi A, Abdullah N, Alvarez R, Bahl V, et al. Validation of the Caprini 
Venous Thromboembolism Risk Assessment Model in Critically Ill Surgical Patients. JAMA 
surgery. 2015
7. Bahl V, Hu HM, Henke PK, Wakefield TW, Campbell DA Jr, Caprini JA. A validation study of a 
retrospective venous thromboembolism risk scoring method. Annals of surgery. 2010; 251(2):344–
50. [PubMed: 19779324] 
8. Pannucci CJ, Bailey SH, Dreszer G, Fisher Wachtman C, Zumsteg JW, Jaber RM, et al. Validation 
of the Caprini risk assessment model in plastic and reconstructive surgery patients. Journal of the 
American College of Surgeons. 2011; 212(1):105–12. [PubMed: 21093314] 
9. Stroud W, Whitworth JM, Miklic M, Schneider KE, Finan MA, Scalici J, et al. Validation of a 
venous thromboembolism risk assessment model in gynecologic oncology. Gynecologic oncology. 
2014; 134(1):160–3. [PubMed: 24796634] 
10. Corr BR, Winter AM, Sammel MD, Chu CS, Gage BF, Hagemann AR. Effectiveness and safety of 
expanded perioperative thromboprophylaxis in complex gynecologic surgery. Gynecologic 
oncology. 2015
11. Shiloach M, Frencher SK Jr, Steeger JE, Rowell KS, Bartzokis K, Tomeh MG, et al. Toward robust 
information: data quality and inter-rater reliability in the American College of Surgeons National 
Surgical Quality Improvement Program. Journal of the American College of Surgeons. 2010; 
210(1):6–16. [PubMed: 20123325] 
12. Program ACoSNSQI. American College of Surgeons National Surgical Quality Improvement 
Program. Chicago, IL: American College of Surgeons; ACS-NSQIP user guide for the 2012 
participant use data file. 
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic 
comorbidity in longitudinal studies: development and validation. Journal of chronic diseases. 
1987; 40(5):373–83. [PubMed: 3558716] 
14. Hua M, Brady JE, Li G. A scoring system to predict unplanned intubation in patients having 
undergone major surgical procedures. Anesthesia and analgesia. 2012; 115(1):88–94. [PubMed: 
22543066] 
BARBER and CLARKE-PEARSON Page 8
Am J Obstet Gynecol. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
15. Commission J. Specifications Manual for National Hospital Inpatient Quality Measures. Feb 24th. 
2016 Available from: http://www.jointcommission.org/
specifications_manual_for_national_hospital_inpatient_quality_measures.aspx
16. Kinnier CV, Ju MH, Kmiecik T, Barnard C, Halverson T, Yang AD, et al. Development of a Novel 
Composite Process Measure for Venous Thromboembolism Prophylaxis. Medical care. 2016; 
54(2):210–7. [PubMed: 26683781] 
17. Barber EL, Neubauer NL, Gossett DR. Risk of venous thromboembolism in abdominal versus 
minimally invasive hysterectomy for benign conditions. American journal of obstetrics and 
gynecology. 2015; 212(5):609, e1–7. [PubMed: 25511239] 
18. Brummer TH, Jalkanen J, Fraser J, Heikkinen AM, Kauko M, Makinen J, et al. FINHYST, a 
prospective study of 5279 hysterectomies: complications and their risk factors. Human 
reproduction. 2011; 26(7):1741–51. [PubMed: 21540244] 
19. Buchberg B, Masoomi H, Lusby K, Choi J, Barleben A, Magno C, et al. Incidence and risk factors 
of venous thromboembolism in colorectal surgery: does laparoscopy impart an advantage? 
Archives of surgery. 2011; 146(6):739–43. [PubMed: 21690452] 
20. Care NCCfA. Venous Thromboembolism: Reducing the Risk of Venous Thromboembolism in 
Patients Admitted to Hospital. London, England: NICE; 2010. 
21. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular 
weight heparin in the prevention of venous thromboembolism in general surgery. The British 
journal of surgery. 2001; 88(7):913–30. [PubMed: 11442521] 
22. Martino MA, George JG, Chen CC, Galic V, Kapoor R, Murray KC, et al. Preoperative enoxaparin 
is safe to use in major gynecologic surgery for prophylaxis of venous thromboembolism: a 
retrospective cohort study. International journal of gynecological cancer: official journal of the 
International Gynecological Cancer Society. 2012; 22(4):681–5. [PubMed: 22343972] 
23. Selby LV, Sovel M, Sjoberg DD, McSweeney M, Douglas D, Jones DR, et al. Preoperative 
Chemoprophylaxis Is Safe in Major Oncology Operations and Effective at Preventing Venous 
Thromboembolism. Journal of the American College of Surgeons. 2016; 222(2):129–37. 
[PubMed: 26711793] 
24. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, et al. Duration of 
prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. The New 
England journal of medicine. 2002; 346(13):975–80. [PubMed: 11919306] 
25. Cain K, Schmeler KM, Langley G, Max O, Ramirez PT, Levenback CF. Patient cost associated 
with filling a prescription for extended-duration venous thromboembolism (VTE) prophylaxis 
following surgery for gynecologic cancer. Gynecologic oncology. 2012; 127(1):18–21. [PubMed: 
22813886] 
26. Fader AN, Weise RM, Sinno AK, Tanner EJ 3rd, Borah BJ, Moriarty JP, et al. Utilization of 
Minimally Invasive Surgery in Endometrial Cancer Care: A Quality and Cost Disparity. Obstetrics 
and gynecology. 2016; 127(1):91–100. [PubMed: 26646127] 
27. Scalici J, Laughlin BB, Finan MA, Wang B, Rocconi RP. The trend towards minimally invasive 
surgery (MIS) for endometrial cancer: an ACS-NSQIP evaluation of surgical outcomes. 
Gynecologic oncology. 2015; 136(3):512–5. [PubMed: 25462206] 
28. Bouchard-Fortier G, Geerts WH, Covens A, Vicus D, Kupets R, Gien LT. Is venous 
thromboprophylaxis necessary in patients undergoing minimally invasive surgery for a 
gynecologic malignancy? Gynecologic oncology. 2014; 134(2):228–32. [PubMed: 24875122] 
29. Leitao MM Jr. Venous thromboembolism and minimally invasive surgery in gynecologic oncology: 
time to re-evaluate and refocus. Gynecologic oncology. 2014; 134(2):217–8. [PubMed: 25090930] 
30. Alberts BD, Woldu SL, Weinberg AC, Danzig MR, Korets R, Badani KK. Venous 
thromboembolism after major urologic oncology surgery: a focus on the incidence and timing of 
thromboembolic events after 27,455 operations. Urology. 2014; 84(4):799–806. [PubMed: 
25156513] 
31. Shapiro R, Vogel JD, Kiran RP. Risk of postoperative venous thromboembolism after laparoscopic 
and open colorectal surgery: an additional benefit of the minimally invasive approach? Diseases of 
the colon and rectum. 2011; 54(12):1496–502. [PubMed: 22067177] 
BARBER and CLARKE-PEARSON Page 9
Am J Obstet Gynecol. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Highest-risk Caprini Group Stratified by Score and Venous Thromboembolism 
Incidence
The relationship between increasing Caprini score and VTE incidence is linear with 
R2=0.93.
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Figure 2. High-risk Rogers Group Stratified by Score and Venous Thromboembolism Incidence
The relationship between increasing Rogers score and VTE incidence is linear with 
R2=0.99.
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Table 1
Demographic and Operative Characteristics
Age (years) 62 (53–70)
BMI (kg/m2) 30.4 (25.1–37.4)
Race
 White 13744 (77.6)
 Black 1358 (7.7)
 Asian 657 (3.7)
 American or Alaskan Native 140 (0.8)
 Unknown 1814 (10.2)
Site of Malignancy
 Uterus 10543 (59.5)
 Ovary 4812 (27.2)
 Cervix 1560 (8.8)
 Vulva/vagina 793 (4.5)
 GTN 5 (0.01)
Procedure type
 Laparotomy 9263 (52.3)
 Minimally-Invasive 7624 (43.0)
 External 826 (4.7)
Charlson comorbidity index score
 0 11923 (67.3)
 1 2890 (16.3)
 2 1435 (8.1)
 3+ 1465 (8.3)
Operating time (min) 159 (112–221)
Length of hospital stay (days) 2.5 (1–4)
Work relative value unit 31.5 (19.3–38.0)
Data is presented as n(%) for categorical variables and median (interquartile range) for continuous variables.
External procedures were defined as procedures in which the abdominal cavity was not entered, such as vulvar/vaginal resections and cervical 
excision procedures.
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Table 2
Patient Categorization into American College of Chest Physicians Risk Groups
Patients were categorized into the ACCP risk groups first by Caprini score and then by Rogers score. The 
group patients were placed in differed depending on which score was used.
ACCP Risk Group Patients Categorized by Caprini Score Patients Categorized by Rogers Score
Caprini Score Patients in Risk Group Rogers Score Patients in Risk Group
Very Low Risk 0 0 (0.0) <7 29 (0.2)
Low Risk 1–2 18 (0.1) 7–10 6532 (36.9)
Moderate Risk 3–4 527 (3.0) >10 11152 (63.0)
High Risk ≥5 17168 (96.9) ** **
ACCP – American College of Chest Physicians
Data is presented as n(%).
**
Rogers scores are not listed for the high risk ACCP group, only a Caprini score is provided.
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Table 3
Observed Venous Thromboembolism Incidence by Risk Group in Currently Available 
VTE Risk Assessment Models
Patients were placed into conventional risk groups defined by the currently available VTE risk assessment 
models themselves.
Observed VTE 95% Confidence interval for VTE incidence (%)
Caprini Score
Low (0–1) 0 --
Moderate (2) 0 (0/18) --
Higher (3–4) 2.47% (13/527) 1.1–3.8
Highest (≥5) 1.75% (300/17168) 1.6–1.9
Rogers Score
Low <7 0 (0.0) --
Medium 7–10 1.03% (67/6532) 0.8–1.3
High >10 2.21% (246/11152) 1.9–2.5
VTE – venous thromboembolism
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Table 4
Observed Venous Thromboembolism Incidence for Highest Risk Groups Sub-stratified by Score
Observed Incidence of VTE 95% confidence interval for VTE incidence 
estimate
Odds ratio 95% confidence interval for OR
Caprini score
5 1.22% (31/2539) 0.79–1.65% referent --
6 1.32% (80/6049) 1.03–1.61% 1.08 0.71–1.65
7 2.07% (121/5849) 1.70–2.43% 1.71 1.15–2.54
≥8 2.47% (68/2749) 1.89–3.05% 2.07 1.35–3.17
Rogers score
11 1.19% (61/5124) 0.89–1.49% referent --
12 2.21% (70/3171) 1.70–2.72% 1.87 1.33–2.65
13 3.11% (44/1414) 2.21–4.02% 2.67 1.80–3.95
14 4.35% (35/839) 2.94–5.76% 3.61 2.37–5.51
≥15 5.96% (36/604) 4.07–7.85% 5.26 3.45–8.01
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